🟢 Tscan Therapeutics is trading 5% up in after-hours trading amid volatility after prior selloff

Tscan Therapeutics is trading at $0.79, up +5.04% in after-hours trading; the move may reflect volatility after the prior selloff, as no separate bullish announcement was identified.

• After-hours trading reversed part of the August 19, 2026 regular-session decline.
• Amgen terminated Tscan’s collaboration, disclosed in an August 18, 2026 filing; the agreement ends November 10, 2026.
• The termination removes potential milestone payments exceeding $500 million.